Stock info

Stock: Fagron (AEX AScX), ISIN: BE0003874915

Last Price 15.52 Max Price 18.16
Min Price 13.59 1 Year return -1.65
Avg. Target 19.90 Expected Return 28.22 %
Sector Health Care Subsector Health Care Eq. & Services
Sell 0 Rating Star full 12x12Star full 12x12Star full 12x12Star full 12x12Star full 12x12
Hold 0 Concensus Cons buy
Buy 5
Annual report 2017
Arseus


Fagron (the former Arseus) is a European Group of corporation that was founded in the year 1998 by the execution of a buy-and-build strategy which was augmented by its strong organic growth. Fagron is an international group of business entities that offers products, services and several notions for professionals and institutions which are active in the healthcare division across Europe, North America, South America, Asia and Australia. Fagron is subdivided into four divisions and is on the go in the markets for magisterial arrangements for pharmacies, dental stuff, medical and surgical goods and medical IT solutions. The Fagron NV is a Belgian company that is situated in Waregem, and the company is listed on Euronext Brussels and Euronext Amsterdam. The operational performances of the Fagron group are determined by the Dutch company Fagron BV. The headquarters of Fagron BV is based in Rotterdam. Fagron service-oriented establishment provides an innovative and customized products and solutions as per their customer needs. Fagron aspires to confine a primary position in each & every market or in the product segment in which it functions.



Fagron with popular home brands, elite distribution agreements and high added value, the company is competent enough to distinguish itself from its rival. Fagron as a Group are considered best to use their knowledge, consumer insight and economies of scale to provide simple, sound and well-organized ways of working. The company provides employment to more than 2,500 employees who work in collaboration and dynamically exchange information and expertise with each other. This permits Fagron to take action quickly, increase productivity and precisely to fulfil customer wishes together with lead to develop their position in the markets. Fagron is looking for a sustainable expansion along with retaining its primary position in certain segments of the specialized healthcare sector and also to develop through organic augmentation and a dynamic buy-and-build approach.



On 5 October 2007 Fagron NV got listed in the NYSE Euronext Brussels and Euronext Amsterdam also its share are incorporated in another index like BEL MID and Amsterdam Small Cap Index (AScX). Fagron offers products, services and entire solutions to the healthcare sector in Europe, North America, South America, Asia and Australia. The activities are subdivided into four divisions. First one is Fagron, which is a global market leader in products and concepts for pharmaceutical compounding. Other is Corilus, which supplies ICT entire solutions for medical specialists in Belgium, Netherlands and France. Another is Healthcare Solutions, which entirely focuses on the dental and medical giving out activities of Fagron. Last but not the least Healthcare Specialties, which concentrates on developing and introducing of pioneering dental and medical solutions and products. Fagron endeavour to get the number 1 position in every market and in each segment in which the company is active. With over 2,500 employees in more than 30 countries globally. In the year 2012 Fagron reported a turnover of 547 Million Euros.


Contact info:Country: BelgiumWebsite: https://fagron.com/en